Trials / Completed
CompletedNCT03144583
Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Sara V. Latorre · Academic / Other
- Sex
- All
- Age
- 2 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To assess the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity \[A3B1\] conjugated with the co-stimulatory regions 4-1BB and CD3z ) safety on patients with leukemia or lymphoma CD19+ resistant or refractory to treatment and with a prognosis of less than 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adult differentiated autologous T-cells | After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused. |
Timeline
- Start date
- 2017-06-15
- Primary completion
- 2022-09-13
- Completion
- 2022-09-13
- First posted
- 2017-05-09
- Last updated
- 2023-08-28
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03144583. Inclusion in this directory is not an endorsement.